Published in AIDS Weekly, January 2nd, 2006
As reported by the company earlier, the data from the in vitro resistance study indicated the high genetic barrier of PPL-100 confirming the potential utility of the drug for first-line treatment of resistant HIV patients. New antiviral drugs with a high genetic barrier (making it more difficult for the virus to develop resistance) are needed to fight the emergence of resistant HIV viruses.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.